FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2019908863> ?p ?o ?g. }

• W2019908863 endingPage "611" @default.
• W2019908863 startingPage "599" @default.
• W2019908863 abstract "Economic analyses of interventions for chronic diseases require evaluations over a long timeframe to illustrate the benefits and costs of treatments. Clinical trials are generally short and carried out in strictly controlled conditions. They are therefore of limited value for economic evaluation aimed at facilitating decisions about resource allocation. The objective of this study was to develop a simulation model that allows integration of data from different sources to calculate the incremental cost-effectiveness and cost-utility of new treatments for overactive bladder. The model compares tolterodine, a new treatment that aims at alleviating symptoms and improving patients' quality of life, to no treatment. Simulations for Sweden are presented as an example. The Markov model combines clinical, observational, and economic data. Markov states are defined based on severity of symptoms of overactive bladder (frequency of voids and leaks). Specific costs for drug treatment and use of sanitary protections as well as utilities are assigned for each state. The effectiveness of tolterodine is based on controlled clinical trials and open long-term extensions of these trials. Outcome is measured as quality-adjusted life years (QALYs) and as the number of months spent in a state with no or very limited symptoms. During the course of 1 year, patients treated with tolterodine spend more time in states with no or limited symptoms compared to those receiving no treatment. Tolterodine-treated patients having a better quality of life during the year. The mean utility of the treated cohort is 0.70, compared to 0.67 in the no-treatment cohort, which is equivalent to the entire cohort moving by one level to a state with less severe symptoms. Mean total costs per patient in the tolterodine arm are SEK8,595 (US $1,131; 1 US$ = 7.6 SEK) compared to SEK3,286 (US$432) in the no-treatment arm. The extra cost due to tolterodine is SEK380 (US$50) per month, which falls within the range of monthly amounts that patients were willing to pay out of pocket for a 25 or 50% improvement of their symptoms in a previous study. The cost for pads is reduced by 23%. The marginal cost per QALY gained with tolterodine is estimated at SEK213,000 (US$28,000). Based on this simulation model, it appears that treatment of overactive bladder with a well-tolerated pharmacological treatment such as tolterodine is cost-effective. Neurourol. Urodynam. 17:599–611, 1998. © 1998 Wiley-Liss, Inc." @default.
• W2019908863 created "2016-06-24" @default.
• W2019908863 creator A5008202613 @default.
• W2019908863 creator A5045027748 @default.
• W2019908863 creator A5074586285 @default.
• W2019908863 date "1998-01-01" @default.
• W2019908863 modified "2023-09-23" @default.
• W2019908863 title "Cost-effectiveness of new treatments for overactive bladder: The example of tolterodine, a new muscarinic agent: A Markov model" @default.
• W2019908863 cites W1998270091 @default.
• W2019908863 cites W2005772964 @default.
• W2019908863 cites W2020969769 @default.
• W2019908863 cites W2024975356 @default.
• W2019908863 cites W2025651318 @default.
• W2019908863 cites W2039558180 @default.
• W2019908863 cites W2043328831 @default.
• W2019908863 cites W2068456101 @default.
• W2019908863 cites W2076009530 @default.
• W2019908863 cites W2091636139 @default.
• W2019908863 cites W2156000474 @default.
• W2019908863 cites W2164654252 @default.
• W2019908863 cites W2473786944 @default.
• W2019908863 doi "https://doi.org/10.1002/(sici)1520-6777(1998)17:6<599::aid-nau4>3.0.co;2-j" @default.
• W2019908863 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/9829424" @default.
• W2019908863 hasPublicationYear "1998" @default.
• W2019908863 type Work @default.
• W2019908863 sameAs 2019908863 @default.
• W2019908863 citedByCount "45" @default.
• W2019908863 countsByYear W20199088632013 @default.
• W2019908863 countsByYear W20199088632014 @default.
• W2019908863 countsByYear W20199088632015 @default.
• W2019908863 countsByYear W20199088632016 @default.
• W2019908863 countsByYear W20199088632018 @default.
• W2019908863 countsByYear W20199088632019 @default.
• W2019908863 crossrefType "journal-article" @default.
• W2019908863 hasAuthorship W2019908863A5008202613 @default.
• W2019908863 hasAuthorship W2019908863A5045027748 @default.
• W2019908863 hasAuthorship W2019908863A5074586285 @default.
• W2019908863 hasConcept C105795698 @default.
• W2019908863 hasConcept C112930515 @default.
• W2019908863 hasConcept C126322002 @default.
• W2019908863 hasConcept C126894567 @default.
• W2019908863 hasConcept C142724271 @default.
• W2019908863 hasConcept C159110408 @default.
• W2019908863 hasConcept C163836022 @default.
• W2019908863 hasConcept C177713679 @default.
• W2019908863 hasConcept C204787440 @default.
• W2019908863 hasConcept C23131810 @default.
• W2019908863 hasConcept C2778941218 @default.
• W2019908863 hasConcept C2779951463 @default.
• W2019908863 hasConcept C2781020410 @default.
• W2019908863 hasConcept C3019080777 @default.
• W2019908863 hasConcept C33923547 @default.
• W2019908863 hasConcept C535046627 @default.
• W2019908863 hasConcept C64332521 @default.
• W2019908863 hasConcept C71924100 @default.
• W2019908863 hasConcept C72563966 @default.
• W2019908863 hasConcept C98763669 @default.
• W2019908863 hasConceptScore W2019908863C105795698 @default.
• W2019908863 hasConceptScore W2019908863C112930515 @default.
• W2019908863 hasConceptScore W2019908863C126322002 @default.
• W2019908863 hasConceptScore W2019908863C126894567 @default.
• W2019908863 hasConceptScore W2019908863C142724271 @default.
• W2019908863 hasConceptScore W2019908863C159110408 @default.
• W2019908863 hasConceptScore W2019908863C163836022 @default.
• W2019908863 hasConceptScore W2019908863C177713679 @default.
• W2019908863 hasConceptScore W2019908863C204787440 @default.
• W2019908863 hasConceptScore W2019908863C23131810 @default.
• W2019908863 hasConceptScore W2019908863C2778941218 @default.
• W2019908863 hasConceptScore W2019908863C2779951463 @default.
• W2019908863 hasConceptScore W2019908863C2781020410 @default.
• W2019908863 hasConceptScore W2019908863C3019080777 @default.
• W2019908863 hasConceptScore W2019908863C33923547 @default.
• W2019908863 hasConceptScore W2019908863C535046627 @default.
• W2019908863 hasConceptScore W2019908863C64332521 @default.
• W2019908863 hasConceptScore W2019908863C71924100 @default.
• W2019908863 hasConceptScore W2019908863C72563966 @default.
• W2019908863 hasConceptScore W2019908863C98763669 @default.
• W2019908863 hasIssue "6" @default.
• W2019908863 hasLocation W20199088631 @default.
• W2019908863 hasLocation W20199088632 @default.
• W2019908863 hasOpenAccess W2019908863 @default.
• W2019908863 hasPrimaryLocation W20199088631 @default.
• W2019908863 hasRelatedWork W1972393115 @default.
• W2019908863 hasRelatedWork W1985264543 @default.
• W2019908863 hasRelatedWork W2004329575 @default.
• W2019908863 hasRelatedWork W2019908863 @default.
• W2019908863 hasRelatedWork W2068095285 @default.
• W2019908863 hasRelatedWork W2092690709 @default.
• W2019908863 hasRelatedWork W2523365756 @default.
• W2019908863 hasRelatedWork W2887535210 @default.
• W2019908863 hasRelatedWork W4242628145 @default.
• W2019908863 hasRelatedWork W4252306930 @default.
• W2019908863 hasVolume "17" @default.
• W2019908863 isParatext "false" @default.
• W2019908863 isRetracted "false" @default.
• W2019908863 magId "2019908863" @default.
• W2019908863 workType "article" @default.